In a recent study published by Nauck et al., all GLP-1 RAs have a common mechanism of action in terms of controlling blood glucose levels, i.e., increased production of insulin during hyperglycemic states, suppressing glucagon secretion, delayed gastric emptying, preventing postprandial glucose spikes, and lowering caloric intake and BMI [3]
A widely held assumption is that Chinese firms could file for DCGI (Drugs Controller General of India) approval and disrupt the Indian market within 12 to 18 months
Unregulated or black-market semaglutide and tirzepatide may contain incorrect doses, impurities, or counterfeit formulations that can cause severe complications including pancreatitis, gallbladder disease, thyroid changes, or allergic reactions
After the initial month and a half, side effects should subside or become more tolerable